Darrell Irvine,Karl Dane Wittrup,Naveen K. Mehta,Kavya Rakhra,Eric Franklin Zhu
申请号：
US15452266
公开号：
US20170252417A1
申请日:
2017.03.07
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a “chaperone-antigen” that increases lymph node uptake； improves an immune response； or a combination thereof relative to the peptide antigen alone. The immune response can be, for example, increased antigen-specific proliferation, enhanced cytokine production, stimulation of differentiation and/or effector functions, promotion of survival, rescue from exhaustion and/or anergy of T cells, or a combination thereof. Chaperon-antigens can also be used to induce tolerance and increase immune suppressive responses. In the most preferred embodiments, the peptide antigen is fused to the chaperone protein to form a fusion protein. The “chaperone-antigen” can be combined with an adjuvant to form a vaccine and administered to a subject to modulate an immune response to the antigen. Methods of increasing immune responses, treating cancer and infectious and inducing tolerance are also provided.
